November 4, 2020 – Thermo Fisher Scientific and the Biopharmaceutical Analysis Training Laboratory (BATL) at Northeastern University, have entered into a collaborative agreement in a bid to advance analytical capabilities and drive innovation across the biopharmaceutical industry in areas including personalized medicine, monoclonal antibodies and gene and cell therapies.
BATL’s globally-recognized technical training programs for regulators, industry personnel and academics, complemented by Thermo Fisher’s leading ultra-high performance liquid chromatography-mass spectrometry (UHPLC-MS) technology, will facilitate the development of cutting-edge analytical solutions and delivery of training designed to meet the current needs of the industry, the companies say.
The implementation of the Thermo Scientific Orbitrap Exploris 240 mass spectrometer and Thermo Scientific Vanquish Duo UHPLC System within BATL’s state-of-the-art training facility will offer the accuracy, precision and reliability required to analyze the complex molecules defining the medicines of the future. Researchers at BATL will be in a position to develop robust, business need-driven, chromatography-based workflows for the streamlined analysis of biotherapeutics and share these methods across the industry to drive analytical advancements.